GSK acquires exclusive rights from Syndivia for ADC
UK pharma major GSK (LSE: GSK) and private French biotech Syndivia company, which is focused on next-generation antibody-drug conjugate (ADCs), today announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a pre-clinical ADC for metastatic castration-resistant prostate cancer (mCRPC).
The deal keeps the spotlight on ADCs, which featured strongly at this month's ESMO conference. From Roche’s (ROG: SIX) $1.4 billion licensing deal to AstraZeneca’s (LSE: AZN) presidential symposium and an avalanche of clinical readouts, the sector everywhere at the meeting. A number of other drugmakers have also been buying into the sector.
Forecasts predict the market for ADCs will expand significantly, with some projecting it to reach over $29 billion by 2032 and others as high as $51.2 billion by 2033, driven by an increasing number of approved drugs and their application in oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze